MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

Kemas kini terakhir: 2 hari lalu, 5:01PM

101.03

-0.80 (-0.79%)

  • 1H -0.79%
  • 5H 0.63%
  • 1B 20.47%
  • 6B 29.08%
  • Tahun Ke Tarikh 1.88%
  • 1T -0.34%
  • 5T 29.22%
Penutupan Terdahulu 101.83
Buka 101.53
Jumlah Dagangan 9,098,392
Purata Dagangan (3B) 13,157,874
Modal Pasaran 252,351,037,440
Harga / Pendapatan (P/E TTM) 13.36
Harga / Pendapatan (P/E Ke hadapan) 10.11
Harga / Jualan (P/S) 3.73
Harga / Buku (P/B) 4.55
Julat 52 Minggu
73.31 (-27%) — 105.84 (4%)
Tarikh Pendapatan 30 Oct 2025
Hasil Dividen (DY TTM) 1.60%
Margin Keuntungan 27.27%
Margin Operasi (TTM) 40.06%
EPS Cair (TTM) 6.88
Pertumbuhan Hasil Suku Tahunan (YOY) -1.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 6.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 71.99%
Nisbah Semasa (MRQ) 1.41
Aliran Tunai Operasi (OCF TTM) 20.88 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 17.12 B
Pulangan Atas Aset (ROA TTM) 13.81%
Pulangan Atas Ekuiti (ROE TTM) 39.29%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Merck & Company, Inc. Menaik Menurun

AISkor Stockmoo

0.3
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal -1.0
Osilator Teknikal 4.0
Purata 0.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
MRK 252 B 1.60% 13.36 4.55
JNJ 488 B 0.61% 19.56 6.24
ABBV 402 B 1.44% 172.39 50.46
PFE 146 B 1.67% 14.94 1.55
BMY 106 B 1.19% 17.49 5.40
GSK 97 B 0.81% 13.71 4.52

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.06%
% Dimiliki oleh Institusi 80.62%
Julat 52 Minggu
73.31 (-27%) — 105.84 (4%)
Julat Harga Sasaran
90.00 (-10%) — 125.00 (23%)
Tinggi 125.00 (Wells Fargo, 23.73%) Beli
Median 105.50 (4.42%)
Rendah 90.00 (Berenberg, -10.92%) Pegang
Purata 106.83 (5.74%)
Jumlah 2 Beli, 4 Pegang
Harga Purata @ Panggilan 91.20
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Goldman Sachs 02 Dec 2025 120.00 (18.78%) Beli 101.03
Wells Fargo 24 Nov 2025 125.00 (23.73%) Beli 100.40
Deutsche Bank 18 Nov 2025 111.00 (9.87%) Pegang 96.43
Morgan Stanley 03 Nov 2025 100.00 (-1.02%) Pegang 82.49
Citigroup 13 Oct 2025 95.00 (-5.97%) Pegang 85.70
Berenberg 17 Sep 2025 90.00 (-10.92%) Pegang 81.14

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
04 Dec 2025 CNBC RFK Jr.'s vaccine panel defers vote on hepatitis B shot for babies until Friday
01 Dec 2025 Pengumuman Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
26 Nov 2025 Pengumuman Merck to Participate in the Citi 2025 Global Healthcare Conference
26 Nov 2025 Pengumuman Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
24 Nov 2025 Pengumuman Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
21 Nov 2025 Pengumuman Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
21 Nov 2025 Pengumuman FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
19 Nov 2025 Pengumuman Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
19 Nov 2025 Pengumuman European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
18 Nov 2025 Pengumuman Merck Announces First-Quarter 2026 Dividend
18 Nov 2025 Pengumuman Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
14 Nov 2025 Pengumuman Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
13 Nov 2025 Pengumuman Merck to Participate in the Jefferies Global Healthcare Conference in London
09 Nov 2025 Pengumuman Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
08 Nov 2025 Pengumuman Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
04 Nov 2025 Pengumuman Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
04 Nov 2025 Pengumuman Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
03 Nov 2025 Pengumuman Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
30 Oct 2025 Pengumuman Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
30 Oct 2025 CNBC Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
29 Oct 2025 Pengumuman Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
29 Oct 2025 Pengumuman European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
28 Oct 2025 Pengumuman Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
28 Oct 2025 Pengumuman Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
27 Oct 2025 Pengumuman U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
23 Oct 2025 Pengumuman eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
23 Oct 2025 Pengumuman FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
23 Oct 2025 Pengumuman Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
21 Oct 2025 Pengumuman Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
20 Oct 2025 Pengumuman Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
20 Oct 2025 Pengumuman KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
19 Oct 2025 Pengumuman Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
18 Oct 2025 Pengumuman KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
18 Oct 2025 Pengumuman KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
18 Oct 2025 Pengumuman KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
16 Oct 2025 Pengumuman Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
15 Oct 2025 Pengumuman Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
09 Oct 2025 Pengumuman Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
09 Oct 2025 Pengumuman Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
07 Oct 2025 Pengumuman Merck Completes Acquisition of Verona Pharma
06 Oct 2025 Pengumuman Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
01 Oct 2025 Pengumuman Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
30 Sep 2025 Pengumuman WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
19 Sep 2025 Pengumuman Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
19 Sep 2025 Pengumuman Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
19 Sep 2025 Pengumuman FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
19 Sep 2025 CNBC RFK Jr.'s vaccine panel postpones vote on whether to delay babies' first hepatitis B shot
17 Sep 2025 Pengumuman Advancing Cancer Research Brings New Hope for Patients Worldwide
15 Sep 2025 Pengumuman Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
11 Sep 2025 Pengumuman CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
07 Sep 2025 Pengumuman Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Papar semua
Hasil Dividen (DY TTM) 1.60%
Purata Hasil Dividen 5T 2.96%
Nisbah Pembayaran 45.93%
Jangkaan Pembayaran Dividen Seterusnya Jan 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
17 Mar 2025 28 Jan 2025 07 Apr 2025 0.81 Tunai
16 Dec 2024 19 Nov 2024 08 Jan 2025 0.81 Tunai
16 Sep 2024 23 Jul 2024 07 Oct 2024 0.77 Tunai
17 Jun 2024 28 May 2024 08 Jul 2024 0.77 Tunai
14 Mar 2024 23 Jan 2024 05 Apr 2024 0.77 Tunai
14 Dec 2023 28 Nov 2023 08 Jan 2024 0.77 Tunai
14 Sep 2023 25 Jul 2023 06 Oct 2023 0.73 Tunai
14 Jun 2023 23 May 2023 10 Jul 2023 0.73 Tunai
14 Mar 2023 24 Jan 2023 10 Apr 2023 0.73 Tunai
14 Dec 2022 29 Nov 2022 09 Jan 2023 0.73 Tunai
14 Sep 2022 26 Jul 2022 07 Oct 2022 0.69 Tunai
14 Jun 2022 24 May 2022 08 Jul 2022 0.69 Tunai
14 Mar 2022 25 Jan 2022 07 Apr 2022 0.69 Tunai
14 Dec 2021 30 Nov 2021 07 Jan 2022 0.69 Tunai
14 Sep 2021 27 Jul 2021 07 Oct 2021 0.65 Tunai
14 Jun 2021 25 May 2021 07 Jul 2021 0.65 Tunai
12 Mar 2021 26 Jan 2021 07 Apr 2021 0.65 Tunai
14 Dec 2020 17 Nov 2020 08 Jan 2021 0.65 Tunai
14 Sep 2020 28 Jul 2020 07 Oct 2020 0.61 Tunai
12 Jun 2020 26 May 2020 07 Jul 2020 0.61 Tunai
13 Mar 2020 28 Jan 2020 07 Apr 2020 0.61 Tunai
13 Dec 2019 20 Nov 2019 08 Jan 2020 0.61 Tunai
13 Sep 2019 24 Jul 2019 07 Oct 2019 0.55 Tunai
14 Jun 2019 29 May 2019 08 Jul 2019 0.55 Tunai
14 Mar 2019 30 Jan 2019 05 Apr 2019 0.55 Tunai
14 Dec 2018 26 Oct 2018 08 Jan 2019 0.55 Tunai
14 Sep 2018 25 Jul 2018 05 Oct 2018 0.48 Tunai
14 Jun 2018 23 May 2018 09 Jul 2018 0.48 Tunai
14 Mar 2018 24 Jan 2018 06 Apr 2018 0.48 Tunai
14 Dec 2017 29 Nov 2017 08 Jan 2018 0.48 Tunai
14 Sep 2017 26 Jul 2017 06 Oct 2017 0.47 Tunai
13 Jun 2017 24 May 2017 10 Jul 2017 0.47 Tunai
13 Mar 2017 28 Feb 2017 07 Apr 2017 0.47 Tunai
13 Dec 2016 22 Nov 2016 09 Jan 2017 0.47 Tunai
13 Sep 2016 26 Jul 2016 07 Oct 2016 0.46 Tunai
13 Jun 2016 25 May 2016 08 Jul 2016 0.46 Tunai
11 Mar 2016 24 Feb 2016 07 Apr 2016 0.46 Tunai
11 Dec 2015 24 Nov 2015 08 Jan 2016 0.46 Tunai
11 Sep 2015 22 Jul 2015 07 Oct 2015 0.45 Tunai
11 Jun 2015 26 May 2015 08 Jul 2015 0.45 Tunai
12 Mar 2015 24 Feb 2015 08 Apr 2015 0.45 Tunai
11 Dec 2014 25 Nov 2014 08 Jan 2015 0.45 Tunai
11 Sep 2014 23 Jul 2014 07 Oct 2014 0.44 Tunai
12 Jun 2014 27 May 2014 08 Jul 2014 0.44 Tunai
13 Mar 2014 25 Feb 2014 07 Apr 2014 0.44 Tunai
12 Dec 2013 26 Nov 2013 08 Jan 2014 0.44 Tunai
12 Sep 2013 23 Jul 2013 07 Oct 2013 0.43 Tunai
13 Jun 2013 28 May 2013 08 Jul 2013 0.43 Tunai
13 Mar 2013 26 Feb 2013 05 Apr 2013 0.43 Tunai
13 Dec 2012 27 Nov 2012 08 Jan 2013 0.43 Tunai
13 Sep 2012 24 Jul 2012 05 Oct 2012 0.42 Tunai
13 Jun 2012 22 May 2012 09 Jul 2012 0.42 Tunai
13 Mar 2012 28 Feb 2012 06 Apr 2012 0.42 Tunai
13 Dec 2011 10 Nov 2011 09 Jan 2012 0.42 Tunai
13 Sep 2011 26 Jul 2011 07 Oct 2011 0.38 Tunai
13 Jun 2011 24 May 2011 08 Jul 2011 0.38 Tunai
11 Mar 2011 22 Feb 2011 07 Apr 2011 0.38 Tunai
13 Dec 2010 23 Nov 2010 07 Jan 2011 0.38 Tunai
13 Sep 2010 27 Jul 2010 07 Oct 2010 0.38 Tunai
11 Jun 2010 26 May 2010 08 Jul 2010 0.38 Tunai
11 Mar 2010 23 Feb 2010 07 Apr 2010 0.38 Tunai
11 Dec 2009 24 Nov 2009 08 Jan 2010 0.38 Tunai
02 Sep 2009 28 Jul 2009 01 Oct 2009 0.38 Tunai
04 Jun 2009 27 May 2009 01 Jul 2009 0.38 Tunai
04 Mar 2009 24 Feb 2009 01 Apr 2009 0.38 Tunai
03 Dec 2008 25 Nov 2008 02 Jan 2009 0.38 Tunai
03 Sep 2008 22 Jul 2008 01 Oct 2008 0.38 Tunai
04 Jun 2008 27 May 2008 01 Jul 2008 0.38 Tunai
05 Mar 2008 26 Feb 2008 01 Apr 2008 0.38 Tunai
05 Dec 2007 27 Nov 2007 02 Jan 2008 0.38 Tunai
05 Sep 2007 24 Jul 2007 01 Oct 2007 0.38 Tunai
06 Jun 2007 22 May 2007 02 Jul 2007 0.38 Tunai
07 Mar 2007 27 Feb 2007 02 Apr 2007 0.38 Tunai
06 Dec 2006 28 Nov 2006 02 Jan 2007 0.38 Tunai
30 Aug 2006 25 Jul 2006 02 Oct 2006 0.38 Tunai
31 May 2006 23 May 2006 03 Jul 2006 0.38 Tunai
31 Aug 2005 26 Jul 2005 03 Oct 2005 0.38 Tunai
01 Jun 2005 24 May 2005 01 Jul 2005 0.38 Tunai
02 Mar 2005 22 Feb 2005 01 Apr 2005 0.38 Tunai
01 Dec 2004 23 Nov 2004 03 Jan 2005 0.38 Tunai
01 Sep 2004 27 Jul 2004 01 Oct 2004 0.38 Tunai
02 Jun 2004 25 May 2004 01 Jul 2004 0.37 Tunai
03 Mar 2004 24 Feb 2004 01 Apr 2004 0.37 Tunai
03 Dec 2003 25 Nov 2003 02 Jan 2004 0.37 Tunai
03 Sep 2003 22 Jul 2003 01 Oct 2003 0.37 Tunai
04 Jun 2003 27 May 2003 01 Jul 2003 0.36 Tunai
05 Mar 2003 25 Feb 2003 01 Apr 2003 0.36 Tunai
04 Dec 2002 26 Nov 2002 02 Jan 2003 0.36 Tunai
04 Sep 2002 23 Jul 2002 01 Oct 2002 0.36 Tunai
05 Jun 2002 28 May 2002 01 Jul 2002 0.35 Tunai
06 Mar 2002 26 Feb 2002 01 Apr 2002 0.35 Tunai
05 Dec 2001 27 Nov 2001 02 Jan 2002 0.35 Tunai
30 Aug 2001 24 Jul 2001 01 Oct 2001 0.35 Tunai
31 May 2001 22 May 2001 02 Jul 2001 0.34 Tunai
07 Mar 2001 27 Feb 2001 02 Apr 2001 0.34 Tunai
06 Dec 2000 28 Nov 2000 02 Jan 2001 0.34 Tunai
30 Aug 2000 25 Jul 2000 02 Oct 2000 0.34 Tunai
31 May 2000 22 May 2000 03 Jul 2000 0.29 Tunai
01 Mar 2000 22 Feb 2000 03 Apr 2000 0.29 Tunai
01 Dec 1999 23 Nov 1999 03 Jan 2000 0.29 Tunai
01 Sep 1999 27 Jul 1999 01 Oct 1999 0.29 Tunai
02 Jun 1999 25 May 1999 01 Jul 1999 0.27 Tunai
03 Mar 1999 23 Feb 1999 01 Apr 1999 0.27 Tunai
02 Dec 1998 24 Nov 1998 04 Jan 1999 0.54 Tunai
02 Sep 1998 28 Jul 1998 01 Oct 1998 0.54 Tunai
03 Jun 1998 26 May 1998 01 Jul 1998 0.45 Tunai
04 Mar 1998 24 Feb 1998 01 Apr 1998 0.45 Tunai
03 Dec 1997 25 Nov 1997 02 Jan 1998 0.45 Tunai
03 Sep 1997 22 Jul 1997 01 Oct 1997 0.45 Tunai
05 Jun 1997 28 May 1997 01 Jul 1997 0.42 Tunai
05 Mar 1997 25 Feb 1997 01 Apr 1997 0.42 Tunai
05 Dec 1996 26 Nov 1996 02 Jan 1997 0.4 Tunai
04 Sep 1996 23 Jul 1996 01 Oct 1996 0.4 Tunai
06 Jun 1996 29 May 1996 01 Jul 1996 0.34 Tunai
06 Mar 1996 27 Feb 1996 01 Apr 1996 0.34 Tunai
06 Dec 1995 28 Nov 1995 02 Jan 1996 0.34 Tunai
05 Sep 1995 25 Jul 1995 02 Oct 1995 0.34 Tunai
02 Jun 1995 23 May 1995 03 Jul 1995 0.3 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.62 2 1.60
2024 3.08 4 3.10
2023 2.92 4 2.68
2022 2.76 4 2.49
2021 2.60 4 3.39
2020 2.44 4 3.13
2019 2.20 4 2.54
2018 1.92 4 2.63
2017 1.88 4 3.50
2016 1.84 4 3.28
2015 1.80 4 3.57
2014 1.76 4 3.25
2013 1.72 4 3.60
2012 1.68 4 4.30
2011 1.52 4 4.23
2010 1.52 4 4.42
2009 1.52 4 4.36
2008 1.52 4 5.24
2007 1.52 4 2.74
2006 0.760 2 1.83
2005 1.52 4 5.01
2004 1.49 4 4.86
2003 1.45 4 3.29
2002 1.41 4 2.61
2001 1.37 4 2.44
2000 1.21 4 1.35
1999 1.37 4 2.14
1998 1.89 4 2.69
1997 1.69 4 3.34
1996 1.42 4 3.74
1995 0.640 2 2.04
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda